Core Insights - Bio-Techne (TECH) reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, exceeding the Zacks Consensus Estimate by 6% and improving from 49 cents in the previous year [1][9] - The company experienced a GAAP loss per share of 11 cents compared to an EPS of 25 cents in the prior-year quarter [2] - For the full year, adjusted EPS was $1.92, surpassing the Zacks Consensus Estimate by 1.1% and reflecting an 8.5% increase from fiscal 2024 [2] Revenue Performance - In the fiscal fourth quarter, Bio-Techne's net sales reached $316.9 million, marking a 3.5% year-over-year increase on a reported basis and 3% on an organic basis, surpassing the Zacks Consensus Estimate by 0.48% [3][9] - Full-year revenues totaled $1.22 billion, a 5.2% improvement from fiscal 2024 on a reported basis and a 5% increase organically, matching the Zacks Consensus Estimate [3] Segment Analysis - Within the Protein Sciences segment, revenues were $226.5 million, up 6% year over year (4% organically) [4] - In the Diagnostics and Spatial Biology segment, sales decreased by 1% year over year to $89.7 million, with an impairment loss of $83.1 million incurred during the quarter due to the Exosome Diagnostics business being classified as held-for-sale [5] Margin and Expense Overview - Bio-Techne's gross profit fell by 2.2% to $198.8 million, with gross margin contracting by 371 basis points to 62.7% due to a 15% rise in the cost of sales [6][9] - Selling, general and administrative expenses increased by 47.2% to $196.6 million, while research and development expenses rose by 8.5% to $26 million [6] Operating Performance - The company reported an operating loss of $23.9 million in the fiscal fourth quarter, a significant decline from the $45.8 million operating profit in the same quarter of the previous year [7][9] Capital Structure - At the end of the fiscal fourth quarter, Bio-Techne had cash and equivalents of $162.2 million, up from $151.8 million at the end of fiscal 2024, while long-term debt obligations increased to $346 million from $319 million [10] Strategic Outlook - Despite market uncertainties, Bio-Techne's results aligned with company expectations, with strong performance in cell therapy and protein analysis instrumentation [11] - The decision to divest the Exosome Diagnostics business is anticipated to enhance profitability and allow a greater focus on high-growth areas, particularly in research and precision diagnostics [11]